logo
Plus   Neg
Share
Email

Novartis: Entresto Shows Metabolic Benefits For HFrEF Patients With Diabetes

Novartis (NVS) reported results of a new post-hoc analysis in a subgroup of patients with reduced ejection fraction heart failure (HFrEF) and diabetes suggesting that Entresto (sacubitril/valsartan) tablets improved glycemic control compared to enalapril. The findings are based on data from PARADIGM-HF, the largest clinical trial ever conducted in systolic heart failure. The company said, Entresto lowered HbA1c levels - a measure of average blood glucose levels for the past two to three months - after one year of treatment for systolic heart failure, and this effect was sustained over three years of study follow-up.

Entresto is indicated to reduce the risk of cardiovascular death and hospitalization for HF in patients with chronic systolic heart failure and reduced ejection fraction. It is not indicated to treat diabetes.

"These results show that in addition to its compelling cardiovascular efficacy, Entresto may have important metabolic benefits for HFrEF patients with diabetes," said Vasant Narasimhan, Global Head, Drug Development and Chief Medical Officer, Novartis.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Member of Congress have reportedly been told President Donald Trump's administration has reached an agreement to put Chinese telecom giant ZTE Corp. back in business. Reports from the New York Times and Reuters said the deal brokered by the Commerce Department would require ZTE to pay a substantial... Delta Air Lines will resume non-stop flights between the U.S. and India next year, almost a decade after it exited the Indian market. The airline said Thursday that its decision to resume non-stop flights from the U.S. to India follows agreements between the U.S. and the governments of the United Arab Emirates and Qatar to address the issue of government subsidies provided to state-owned carriers. Mortgage rates continued their upward trend this week and hit a seven-year high, even as housing demand remained robust. According to data released Thursday by mortgage finance provider Freddie Mac, the 30-year fixed-rate mortgage rose to 4.66 percent in the week ending May 24, from 4.61 percent in the prior week and 3.95 percent a year ago. This is also the highest level since May 5, 2011.
Follow RTT